Early research on proton craniospinal irradiation (pCSI) reported potential benefits for patients with LMD. Notably, the final analysis of a randomized phase 2 trial by Yang et al of 63 patients with ...
Many of cancer’s effects are visible — but the causes aren’t always so obvious. There are hundreds of different types of cancer, and far more causes. "Cancer-causing agents, known as carcinogens, can ...
Rhenium (186Re) obisbemeda (Plus Therapeutics) shows potential to address the unmet need of new treatment options for patients with breast cancer and leptomeningeal metastases and will continue to be ...
Leptomeningeal metastasis is a deadly consequence of cancer that creates an unusually inflamed environment around the brain and spinal cord. One of the inflammatory signalling molecules found in ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. UCLA researchers are working on a paper-based test to ...
Plus Therapeutics, Inc. announced that the U.S. FDA has granted Orphan Drug Designation to its investigational therapy, Rhenium (186Re) Obisbemeda, for treating leptomeningeal metastases in lung ...
Single intrathecal dose of Rhenium (186 Re) Obisbemeda delivers favorable responses in cerebrospinal fluid circulating tumor cell count, imaging, and clinical evaluation Initiate ReSPECT-LM Phase 1b ...
Controlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024 AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback